Anti-GLUD1 + GLUD2 antibody [EPR11369(B)]

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (AB166618)

Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling GLUD1 with ab166618 at 1/250 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (AB166618)

ab166618 showing +ve staining in Human normal brain.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (AB166618)

ab166618 showing +ve staining in Human normal tonsil.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (AB166618)

ab166618 showing +ve staining in Human normal kidney.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (AB166618)

Immunohistochemical analysis of paraffin-embedded Human skeletal muscle tissue labeling GLUD1 with ab166618 at 1/250 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (AB166618)

ab166618 showing +ve staining in Human normal colon.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• WB

Unknown

Western blot - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (AB166618)

All lanes:

Western blot - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (ab166618) at 1/10000 dilution

Lane 1:

Human fetal liver lysates at 10 µg

Lane 2:

HepG2 lysates at 10 µg

Lane 3:

HeLa lysates at 10 µg

Lane 4:

293T lysates at 10 µg

false

• WB

CiteAb

Western blot - Anti-GLUD1 + GLUD2 antibody [EPR11369(B)] (AB166618)

GLUD1 + GLUD2 western blot using anti-GLUD1 + GLUD2 antibody [EPR11369(B)] ab166618. Publication image and figure legend from Duan, G., Shi, M., et al., 2018, Sci Rep, PubMed 29511244.

ab166618 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab166618 please see the product overview.

Gln catabolism was enhanced in resistant cells to sustain cellular redox homeostasis. (A) qRT-PCR shows the relative expression of GLS mRNA in HeLa and HeLa/ddp cells. (B) Western blot analysis for GLS and β-Actin expression in HeLa and HeLa/ddp cells. (C) Western blot analysis of KRAS, GOT1, GLUD1 and β-Actin expression in HeLa and HeLa/ddp cells. (D) qRT-PCR shows the relative expression of KRAS mRNA in HeLa and HeLa/ddp cells. (E) The expression of GOT1 and β-Actin was determined by Western blot analysis in HeLa/ddp cells transfected with negative control shRNA or two independent shRNAs targeting GOT1 for 48 h. (F) HeLa/ddp cells were transfected with a negative control shRNA or shRNA targeting GOT1 for 48 h, and then the cells were seeded in 6-well plates. The medium was replaced the following day with Gln-free medium, and GSH (4 mM) was added to the medium following Gln withdrawal. (G) Relative clonogenic growth of HeLa and HeLa/ddp cells. GSH (4 mM) was added to the medium following Gln withdrawal. (H and I) Ralative proliferation of HeLa and HeLa/ddp cells determined by CFSE assay; the medium was replaced with corresponding medium and supplemented with GSH (4 mM) the following day. The error bars represent the s.d. of triplicate wells of a representative experiment (A–I). (J) Xenograft growth of HeLa/ddp cells expressing a control shRNA or a shRNA targeting GOT1 in mice (n = 5). The error bars represent the s.e.m.

false